e-Article
Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablets (Sevikar[R]) in older patients with essential hypertension: Subgroup analysis from the Sevikar study
Document Type
Academic Journal
Author
Cui, Zhaoqiang; Qiu, Zhaohui; Cheng, Wenli; Hu, Wei; Ma, Genshan; Cai, Xiaojun; Jin, Yafei; Zhao, Yi; He, Liqun; Li, Ying; Bu, Peili; Chen, Xiaoping; Wang, Ruxing; Chen, Lin; Dong, Peng; Feng, Liuliu; Han, Xuebin; Hong, Mei; Hou, Yinglong; Liao, Minlei; Wang, Mingliang; Wang, Xiaoyan; Xie, Jianhong; Xu, Yawei; Wang, Zhenxing; Huang, Kai; Li, Yongle; Li, Dongsheng; Ji, Xiaojun; Huang, Jing; Wang, Jun; Fang, Danhong; Wang, Jian'An; Tang, Lijiang; Liu, Yingwu; Fu, Guosheng; Du, Juan; Wang, Ling; Liu, Mengqi; Ge, Junbo
Source
Experimental and Therapeutic Medicine. February 2024, Vol. 27 Issue 2
Subject
Language
English
ISSN
1792-0981
Abstract
Introduction Essential hypertension is a highly prevalent chronic disease with >30% of adults having hypertension in 2010 globally; the disease is associated with cardio- and cerebrovascular diseases, such as stroke, [...]
Essential hypertension is a notable threat for the older (age, [greater than or equal to] 65 years) population. However, to the best of our knowledge, a real-world study assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablets in older Chinese patients with essential hypertension has not been performed. Therefore, the present study aimed to evaluate the efficacy and safety of OM-AML tablets in these patients. A total of 463 older Chinese patients with essential hypertension treated with OM-AML (20/5 mg) tablets (Sevikar[R]) were analyzed in a prospective, single-arm, multi-center, real-world study. Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, and at week (W)4 and W8 after OM-AML tablet administration were measured. The mean [+ or -] standard error change of SeSBP/SeDBP was -10.3[+ or -]0.8/-4.6[+ or -]0.5 and -12.5[+ or -]0.8/-5.6 [+ or -]0.5 mmHg at W4 and W8, respectively. At W4, 74.1 and 26.8% of patients achieved BP target according to the China and American Heart Association (AHA) criteria, while at W8, 78.0 and 38.7% of patients reached these BP targets accordingly. Finally, 76.5 and 80.5% of patients achieved BP response at W4 and W8, respectively. Furthermore, home-measured SeSBP and SeDBP were significantly decreased from W1 to W8 (both P Key words: olmesartan medoxomil-amlodipine besylate tablet, essential hypertension, blood pressure target, adverse event
Essential hypertension is a notable threat for the older (age, [greater than or equal to] 65 years) population. However, to the best of our knowledge, a real-world study assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablets in older Chinese patients with essential hypertension has not been performed. Therefore, the present study aimed to evaluate the efficacy and safety of OM-AML tablets in these patients. A total of 463 older Chinese patients with essential hypertension treated with OM-AML (20/5 mg) tablets (Sevikar[R]) were analyzed in a prospective, single-arm, multi-center, real-world study. Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, and at week (W)4 and W8 after OM-AML tablet administration were measured. The mean [+ or -] standard error change of SeSBP/SeDBP was -10.3[+ or -]0.8/-4.6[+ or -]0.5 and -12.5[+ or -]0.8/-5.6 [+ or -]0.5 mmHg at W4 and W8, respectively. At W4, 74.1 and 26.8% of patients achieved BP target according to the China and American Heart Association (AHA) criteria, while at W8, 78.0 and 38.7% of patients reached these BP targets accordingly. Finally, 76.5 and 80.5% of patients achieved BP response at W4 and W8, respectively. Furthermore, home-measured SeSBP and SeDBP were significantly decreased from W1 to W8 (both P Key words: olmesartan medoxomil-amlodipine besylate tablet, essential hypertension, blood pressure target, adverse event